SCHEMBL1717801

SCHEMBL1717801

CCOC(=O)c1c(C)n(-c2ccccc2)c(=O)c2ccc(F)cc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
RECQL P46063 1/20 0.55
MAPT P10636 4/20 0.53
TP53 P04637 4/20 0.53
THRB P10828 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
GAA P10253 2/20 0.50
ALDH1A1 P00352 2/20 0.50
CHEK1 O14757 1/20 0.49
AURKA O14965 1/20 0.49
NTRK1 P04629 1/20 0.49
FYN P06241 1/20 0.49
MET P08581 1/20 0.49
PDGFRB P09619 1/20 0.49
PIM1 P11309 1/20 0.49
FGFR1 P11362 1/20 0.49
PDGFRA P16234 1/20 0.49
LTK P29376 1/20 0.49
GRK5 P34947 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1717992 0.95 MEN1 (0.60) MEN1KMT2ARECQLMAPTTP53
SCHEMBL1717020 0.88 MEN1 (0.62) MEN1KMT2ARECQLMAPTTP53
SCHEMBL1717101 0.87 RECQL (0.55) MEN1KMT2ARECQLMAPTTP53
SCHEMBL1717720 0.86 RECQL (0.67) MEN1KMT2ARECQLMAPTTP53
SCHEMBL1717712 0.86 MEN1 (0.54) MEN1KMT2ARECQLMAPTTP53
SCHEMBL1717130 0.85 GAA (0.54) MAPTSMN1; SMN2GAAALDH1A1LMNA
SCHEMBL1718672 0.83 MEN1 (0.62) MEN1KMT2ARECQLMAPTTP53
SCHEMBL2675778 0.81 MEN1 (0.60) MEN1KMT2ARECQLMAPTTP53
SCHEMBL1719451 0.81 MEN1 (0.60) MEN1KMT2ARECQLMAPTTP53
SCHEMBL1717998 0.80 GAA (0.54) MAPTSMN1; SMN2GAAALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
US-8173639-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-05-08 US disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
EP-2150534-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-01-11 EP disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2009-06-04 US disclosed
WO-2008131779-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143402-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 MEN1 3960/4885KMT2A 1850/4885RECQL 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.